Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in BRCA-Mutated Cancers
NCT04673448Phase 1Active, not recruiting
- Sponsor
- University of Washington
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib and dostarlimab in breast cancer, pancreatic cancer (PC), ovarian cancer and 2 more, sponsored by University of Washington. Primary endpoint: Best objective response at 5 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
breast cancerpancreatic cancer (PC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04673448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673448.